The Journal of Pediatrics
Volume 153, Issue 3 , Pages 327-332.e1, September 2008

Poor Immune Responses to a Birth Dose of Diphtheria, Tetanus, and Acellular Pertussis Vaccine

  • Natasha B. Halasa, MD, MPH

      Affiliations

    • Departments of Pediatrics, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN
    • Corresponding Author InformationReprint requests: Natasha Halasa, MD, MPH, D7232 Medical Center N., 1161 21st Ave. S., Nashville, TN 37232
  • ,
  • Alice O'Shea, RN

      Affiliations

    • Departments of Pediatrics, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN
  • ,
  • Jian R. Shi, MD

      Affiliations

    • Departments of Pediatrics, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN
  • ,
  • Bonnie J. LaFleur, PhD, MPH

      Affiliations

    • Section of Biostatistics, Department of Pediatrics, University of Utah, Salt Lake City, UT
  • ,
  • Kathryn M. Edwards, MD

      Affiliations

    • Departments of Pediatrics, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, TN

Received 13 September 2007; received in revised form 18 January 2008; accepted 12 March 2008. published online 28 April 2008.

Objectives

To evaluate the safety and immunogenicity of an additional birth dose of diphtheria, tetanus, and acellular pertussis vaccine (DTaP).

Study design

Fifty infants between 2 to 14 days of age were randomly assigned to receive either DTaP and hepatitis B vaccines (experimental) or hepatitis B alone (control) at birth. At 2, 4, 6, and 17 months of age, DTaP and routine vaccines were administered to both groups. Safety data were collected after each dose, and sera were obtained at birth, 6, 7, 17, and 18 months. Immune responses to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae were measured by enzyme-linked immunosorbent assay; responses to other vaccines were assessed.

Results

No differences were seen between the 2 groups in either local or systemic reactions; all vaccines were well tolerated. Compared with the control group, infants in the experimental group demonstrated significantly lower geometric mean antibody concentrations for pertussis toxin and pertactin 6, 7, and 18 months, for fimbrae at 6, 7, 17, and 18 months, and for FHA at 18 months, and lower geometric mean antibody concentrations for diphtheria at 7 months. Immune responses to all other vaccine antigens were comparable.

Conclusion

Administration of an additional dose of DTaP at birth was safe but was associated with a significantly lower response to diphtheria and 3 of 4 pertussis antigens compared with controls.

Abbreviations: DTaP, Diphtheria and tetanus toxoids and acellular pertussis vaccine, DTP, Diphtheria and tetanus toxoids, ELISA, Enzyme-linked immunosorbent assay, FDA, Food and Drug Administration, FHA, Filamentous hemagglutinin, FIM, Fimbriae 2 and 3, GMC, Geometric mean concentration, HBS, Hepatitis B surface, HepB, Hepatitis B vaccine, Hib, Haemophilus influenzae type b conjugate vaccine, IgG, Immunoglobulin G, IPV, Inactivated trivalent poliovirus vaccine, MMR, Measles mumps rubella, PCV7, Pneumococcal conjugate vaccine 7-valent, PRN, Pertactin, PRP, Polyribosylribitol phosphate, PT, Pertussis toxoid, V, Varicella virus vaccine live

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by an NIH-sponsored Mentored Institutional Clinical Research Scholar Program (K12 RR-017697); an NIH-funded K 23 award (1K23AI064246-01), and an independent investigator-initiated grant from sanofi-pasteur. Facilities for study conduct were also provided in the Vanderbilt General Clinical Research Center (M01 RR-00095), supported by the National Center for Research Resources, National Institutes of Health.

PII: S0022-3476(08)00201-1

doi:10.1016/j.jpeds.2008.03.011

Refers to article:

  • Blame Vaccine Interference, Not Neonatal Immunization, for Suboptimal Responses after Neonatal Diphtheria, Tetanus, and Acellular Pertussis Immunization

    Claire-Anne Siegrist
    The Journal of Pediatrics September 2008 (Vol. 153, Issue 3, Pages 305-307)

The Journal of Pediatrics
Volume 153, Issue 3 , Pages 327-332.e1, September 2008